This file is part of IDEAS, which uses RePEc data


[ Papers | Articles | Software | Books | Chapters | Authors | Institutions | JEL Classification | NEP reports | Search | New papers by email | Author registration | Rankings | Volunteers | FAQ | Blog | Help! ]

The effect of direct-to-consumer pharmaceutical advertising on health choices: an empirical investigation using panel data

Author info | Abstract | Publisher info | Download info | Related research | Statistics
Author Info
Mark Showalter
James Cardon

Additional information is available for the following registered author(s):

Abstract

In 1997, the FDA relaxed regulations on direct-to-consumer (DTC) advertising for pharmaceutical products. This has led to a substantial increase in such expenditures which in turn raises some important public policy questions. For example, has this increase in DTC advertising affected the doctor-patient relationship in a way that distorts optimal choice of care? The benign view of such advertising is that DTC ads are simply informative and thus lead consumers to obtain better care than would have occurred otherwise. An opposing view is that DTC advertising entices consumers to obtain treatments that are unnecessary or more expensive than “optimal” treatment (For general discussions, see Berndt et al, AER 1995; Iizuka, T. and G. Jin, working paper 2002). This paper will investigate the effects of DTC advertising on a relatively rich panel data of roughly 50,000 individuals obtained from an insurance firm. Included in this data are all prescription drugs purchases for covered individuals from 1997-2001, as well as all other health services provided for the individuals through the insurance company. Demographic variables are also available for the individuals. We will use monthly DTC expenditures in specific geographic areas for a set of pharmaceutical products (provided by a major pharmaceutical firm) to measure the impact of expenditures on 1) physician visits, and 2) prescriptions written for the product, controlling for other observable characteristics. We will also examine the impact on brand switching within a therapeutic class. We build on the work of others by exploiting the panel nature of the data, using recently-developed estimators for non-linear panel data models (Honore, B. and E. Kyriazidou, ECM, 2000).

Download Info
To our knowledge, this item is not available for download. To find whether it is available, there are three options:
1. Check below under "Related research" whether another version of this item is available online.
2. Check on the provider's web page whether it is in fact available.
3. Perform a search for a similarly titled item that would be available.

Publisher Info
Paper provided by Econometric Society in its series Econometric Society 2004 North American Winter Meetings with number 550.

Download reference. The following formats are available: HTML (with abstract), plain text (with abstract), BibTeX, RIS (EndNote, RefMan, ProCite), ReDIF
Length:
Date of creation: 11 Aug 2004
Date of revision:
Handle: RePEc:ecm:nawm04:550

Contact details of provider:
Phone: 1 212 998 3820
Fax: 1 212 995 4487
Email:
Web page: http://www.econometricsociety.org/pastmeetings.asp
More information through EDIRC

For technical questions regarding this item, or to correct its listing, contact: (Christopher F. Baum).

Related research
Keywords: Pharmaceuticals; DTC advertising; panel data estimation;

Find related papers by JEL classification:
I1 - Health, Education, and Welfare - - Health
L1 - Industrial Organization - - Market Structure, Firm Strategy, and Market Performance

Statistics
Access and download statistics

Did you know? There are over 21000 authors registered on RePEc Author Service.

This page was last updated on 2009-12-2.


This information is provided to you by IDEAS at the Department of Economics, College of Liberal Arts and Sciences, University of Connecticut using RePEc data on a server sponsored by the Society for Economic Dynamics.